| Literature DB >> 21492476 |
Sven-T Liffers1, Abdelouahid Maghnouj, Johanna B Munding, René Jackstadt, Ulrike Herbrand, Thomas Schulenborg, Katrin Marcus, Susanne Klein-Scory, Wolff Schmiegel, Irmgard Schwarte-Waldhoff, Helmut E Meyer, Kai Stühler, Stephan A Hahn.
Abstract
BACKGROUND: Inactivating mutations of SMAD4 are frequent in metastatic colorectal carcinomas. In previous analyses, we were able to show that restoration of Smad4 expression in Smad4-deficient SW480 human colon carcinoma cells was adequate to suppress tumorigenicity and invasive potential, whereas in vitro cell growth was not affected. Using this cellular model system, we searched for new Smad4 targets comparing nuclear subproteomes derived from Smad4 re-expressing and Smad4 negative SW480 cells.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21492476 PMCID: PMC3095566 DOI: 10.1186/1471-2407-11-137
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Differential proteome analysis of Smad4 re-expressing and negative SW480 cells. A) A representative example of the 2D-DIGE analyses is shown. Differentially expressed proteins are labeled by an arrow. The protein spot signals derived from the nuclear lysates of Smad4 negative cells are shown in green and those from Smad4 re-expressing cells in red. The protein names corresponding to each numbered spot are given in table 1. Spot numbers 10 and 11 mark the KRT23 spots. B) and C) Expression levels of the two KRT23 spots relative to the protein standard according to the dye swop experiment (neg., Smad4 negative SW480 cells; pos., Smad4 re-expressing SW480 cells) D) Expression of KRT23 analyzed by Northern blotting.
Smad4 target proteins identified by DIGE coupled with MALDI-TOF-MS
| Spot | Accession No | Protein | Profound | Sequence | No. of Peptides | |
|---|---|---|---|---|---|---|
| matched | detected | |||||
| 1 | gi|44890631 | tumor rejection antigen (gp96) 1 | 2.4 | 14.6 | 15 | 21 |
| 3 | gi|5031755 | heterogeneous nuclear ribonucleoprotein R | 2.5 | 23.4 | 12 | 20 |
| 4 | gi|181573 | cytokeratin 8 | 2.4 | 29.0 | 11 | 15 |
| 6 | gi|4506439 | retinoblastoma binding protein 7 | 2.4 | 26.4 | 12 | 20 |
| 7 | gi|4503471 | eukaryotic translation elongation factor 1 alpha 1 | 1.0 | 12.6 | 6 | 13 |
| 8 | gi|4503471 | eukaryotic translation elongation factor 1 alpha 1 | 1.8 | 20.3 | 8 | 20 |
| 9 | gi|4503471 | eukaryotic translation elongation factor 1 alpha 1 | 1.3 | 18.8 | 6 | 20 |
| 10 | gi|27894339 | cytokeratin 23 | 2.4 | 60.2 | 26 | 47 |
| 11 | gi|27894339 | cytokeratin 23 | 2.2 | 34.4 | 17 | 26 |
| 15 | gi|30311 | cytokeratin 18 | 2.4 | 22.9 | 12 | 21 |
| 16 | gi|1633054 | cyclophilin A | 2.2 | 48.2 | 12 | 23 |
| 17 | gi|1633054 | cyclophilin A | 1.6 | 51.2 | 7 | 20 |
Only spots with unequivocal identification by MALDI-TOF-MS are included in this table.
Figure 2Tandem affinity purification of Keratin 23. Confocal immunofluorescence images of SW480 cells overexpressing KRT23. A) Smad4 re-expressing SW480 cells B) Smad4 negative SW480 cells. KRT23 was visualized by α-Flag M2 antibody. C) FLAG eluates from the tandem affinity purification experiments with TAP-KRT23 were separated on a standard 1D-PAGE and proteins visualized by silver staining. The protein names corresponding to each numbered band given in table 2.
KRT23 interacting proteins identified by TAP followed by LC-MS/MS
| Lane | NCBI | Protein identified | Peptides | Mascot |
|---|---|---|---|---|
| 1 | gi|40849944 | plectin 1 isoform 11 | ELYQQLQR | 59 |
| LSVAAQEAAR | 56 | |||
| FAEQTLR | 46 | |||
| LAAIGEATR | 46 | |||
| LTVDEAVR | 44 | |||
| DLSELGSVR | 41 | |||
| GLVEDTLR | 41 | |||
| VSIYEAM*R | 33 | |||
| DVAEVDTVR | 32 | |||
| 2 | gi|5729877 | HSP70 | NQVAM*NPTNTVFDAK | 76 |
| VEIIANDQGNR | 74 | |||
| DAGTIAGLNVLR | 73 | |||
| LLQDFFNGK | 45 | |||
| EIAEAYLGK | 43 | |||
| NSLESYAFNM*K | 38 | |||
| LIGDAAK | 35 | |||
| ITITNDK | 33 | |||
| 3 | gi|31542947 | HSP60 | NAGVEGSLIVEK | 85 |
| VTDALNATR | 75 | |||
| VGGTSDVEVNEK | 63 | |||
| VGLQVVAVK | 62 | |||
| TVIIEQSWGSPK | 59 | |||
| LSDGVAVLK | 52 | |||
| DDAM*LLK | 47 | |||
| EIGNIISDAM*K | 45 | |||
| APGFGDNR | 43 | |||
| IGIEIIK | 41 | |||
| VGEVIVTK | 41 | |||
| NAGVEGSLIVEK | 33 | |||
| 4 | gi|181573 | cytokeratin 8 | YEELQSLAGK | 73 |
| LSELEAALQR | 71 | |||
| SLDM*DSIIAEVK | 65 | |||
| ASLEAAIADAEQR | 59 | |||
| KLLEGEESR | 57 | |||
| LESGM*QNM*SIHTK | 56 | |||
| TEM*ENEFVLIK | 55 | |||
| LQAEIEGLK | 55 | |||
| ISSSSFSR | 55 | |||
| SLDM*DSIIAEVK | 52 | |||
| ELQSQISDTSVVLSM*DNSR | 48 | |||
| TEISEM*NR | 46 | |||
| LLEGEESR | 45 | |||
| SRAEAESM*YQIK | 44 | |||
| FASFIDK | 44 | |||
| NKYEDEINKR | 40 | |||
| DVDEAYM*NK | 38 | |||
| SYTSGPGSR | 36 | |||
| GELAIK | 35 | |||
| AEAESM*YQIK | 34 | |||
| YEDEINKR | 33 | |||
| QLYEEEIR | 33 | |||
| FLEQQNK | 33 | |||
| 5 | gi|20306864 | cytokeratin 23 | SALENM*LSETQSR | 106 |
| EQSAAM*SQEAASPATVQSR | 59 | |||
| DLEIEVEGLR | 58 | |||
| LLEGESEGTR | 57 | |||
| ATM*QNLNDR | 56 | |||
| AITQETINGR | 49 | |||
| MAVDDFNLK | 47 | |||
| M*AVDDFNLK | 47 | |||
| ISLSFTTR | 44 | |||
| YENEHSFK | 42 | |||
| LASYVEK | 40 | |||
| APTVHGGAGGAR | 38 | |||
| ALEEANM*K | 35 | |||
| 6 | gi|30311 | cytokeratin 18 | AQIFANTVDNAR | 80 |
| LEAEIATYR | 70 | |||
| TVQSLEIDLDSM*R | 67 | |||
| ETM*QSLNDR | 53 | |||
| LASYLDR | 51 | |||
| LAADDFR | 50 | |||
| KVIDDTNITR | 46 | |||
| VIDDTNITR | 45 | |||
| STFSTNYR | 43 | |||
| SLETENR | 42 | |||
| AQYDELAR | 40 | |||
| YETELAM*R | 38 | |||
| DWSHYFK | 36 | |||
| 7 | gi|67464424 | 14-3-3 ε | VAGM*DVELTVEER | 95 |
| EAAENSLVAYK | 84 | |||
| YLAEFATGNDR | 72 | |||
| HLIPAANTGESK | 54 | |||
| LAEQAER | 50 | |||
| DSTLIM*QLLR | 48 | |||
| YDEM*VESM*K | 47 | |||
| IISSIEQK | 44 | |||
| QM*VETELK | 36 | |||
| NLLSVAYK | 33 | |||
| 8 | gi|21464101 | 14-3-3 γ | NVTELNEPLSNEER | 71 |
| YLAEVATGEK | 66 | |||
| LAEQAER | 62 | |||
| DSTLIM*QLLR | 58 | |||
| YDDM*AAAM*K | 56 | |||
| NLLSVAYK | 55 | |||
| VISSIEQK | 42 | |||
| ATVVESSEK | 40 | |||
| AYSEAHEISK | 35 |
Figure 3Interaction of Keratin 23 with 14-3-3ε. A) Endogenous 14-3-3ε and 14-3-3γ expression levels of Smad4 re-expressing and Smad4 negative SW480 cells. 20 μg whole cell lysates derived from Smad4 re-expressing and Smad4 negative cells were subjected to SDS-PAGE. Flag-tagged KRT23 and VSV-G-tagged 14-3-3ε were transfected into HEK 293T cells as indicated. B) Confirmation of KRT23-14-3-3ε interaction: cell lysates were immunoprecipitated with anti-Flag antibody and blotted as indicated. C) KRT23 expression leads to cytoplasmic sequestration of 14-3-3ε: following fractionation into cytoplasmic and nuclear fractions, proteins were subjected to Western blot analysis with the indicated antibodies. Anti-lamin B and anti-β-tubulin were used as marker proteins for the purity of the fractions. C, cytoplasmic fraction, N, nuclear fraction. A representative blot from three independent experiments is shown.
Figure 4Cellular localization of 14-3-3ε according to the Smad4 expression and KRT23 knock-down status of SW480 cells. A) Confocal immunofluorescence images of SW480 cells. The cellular localization of 14-3-3ε was analyzed in Smad4 negative and Smad4 re-expressing SW480 cells. KRT23 knock-down was achieved by stable overexpression of shKRT1010 in Smad4 re-expressing cells. The cells were double stained with antibodies to 14-3-3ε (red) and the cytosolic marker tubulin (green). B) Validation of Keratin 23 knock-down efficiency. The Keratin 23 expression was monitored by quantitative RT-PCR in stably sh-KRT23 overexpressing SW480 cells as indicated. Each condition was measured in triplicates and normalized to B2M.